Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
iinnovate-1
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT03215030 ↗
- Terminated
- Teva Branded Pharmaceutical Products R&D LLC
- Focused
We haven't built an HCP commentary report on iinnovate-1 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on iinnovate-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 1 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Multiple Myeloma
- Interventions
- Modakafusp alfa; Dexamethasone
- Arms
- Part 1 (Dose Escalation) Schedule A · Experimental
- Part 1 (Dose Escalation) Schedule B · Experimental
- Part 1 (Dose Escalation) Schedule C · Experimental
- Part 1 (Dose Escalation) Schedule D · Experimental
- Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa · Experimental
- Part 2 (Dose Expansion):ScheduleC:Modakafusp Alfa+Dexamethasone · Experimental
- Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa · Experimental
- Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa + Dexamethasone · Experimental
- Part 3 (Dose Extension): Modakafusp Alfa 120 mg · Experimental
- Part 3 (Dose Extension): Modakafusp Alfa 240 mg · Experimental
- Japan Lead-in: Modakafusp Alfa 60 mg · Experimental
- Japan Lead-in: Modakafusp Alfa 120 mg · Experimental
- Enrollment
- 272
- Primary outcomes
- Part 1: Percentage of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs)
- Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
- Part 1: Percentage of Participants Reporting One or More Grade 3 or Higher TEAEs
- Part 1: Percentage of Participants Reporting One or More Serious Treatment-emergent Adverse Events (Serious TEAEs)
- Part 1: Percentage of Participants Who Discontinued the Treatment Because of TEAE
- Part 1: Percentage of Participants With TEAEs Resulting in Dose Modifications: Dose Delay
- Part 1: Percentage of Participants With TEAEs Resulting in Dose Modifications: Dose Interruptions
- Part 1: Percentage of Participants With TEAEs Resulting in Dose Modifications: Dose Reductions
- Part 1: Percentage of Participants With Clinically Significant Laboratory Values
- Part 1: Percentage of Participants With Clinically Significant Vital Signs Measurements
- Part 2: Overall Response Rate (ORR)
- Part 3: Overall Response Rate (ORR) Assessed by Independent Review Committee (IRC)
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Start
- Oct 4, 2017
- Primary completion
- Jul 1, 2024
- Results posted
- Yes
- Registry record
- NCT03215030 · updated Jan 29, 2026
Publications
linked from the registry- Holstein SA, Atrash S, Mian H, Dimopoulos MA, Schjesvold F, Popat R, Shah N, Gatt ME, Gocke CB, Frenzel L, Touzeau C, Beksac M, Manier S, Magen H, Travis P, Nadeem O, Suryanarayan K, Li C, Li S, Nelson A, Cherepanov D, Parot X, Vogl DT. A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma. Blood. 2025 Aug 28;146(9):1051-1064. doi: 10.1182/blood.2024027873. PubMed 40279508
- Vogl DT, Atrash S, Holstein SA, Nadeem O, Benson D, Chaudry M, Biran N, Suryanarayan K, Li C, Liu Y, Collins S, Parot X, Kaufman JL. Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma. Blood. 2025 Feb 27;145(9):944-955. doi: 10.1182/blood.2024026124. PubMed 39630057